EPHA2 and cancer: Antibodies (Abs) that agonize and trigger internalization of EphA2 can be conjugated to cytotoxic drugs, and these ADCs have been used to deliver the drugs to cancer cells overexpressing EphA2 (Jackson et al., 2008; Lee et al., 2009).